Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update

Rhea-AI Summary

Aadi Bioscience, Inc. will host a conference call and webcast on November 8, 2023, to report third quarter 2023 financial results and provide an operational update. Participants can access the live webcast on the company's website and register in advance to participate via telephone. A replay of the conference call and webcast will be available on the company's website for at least 30 days.

Company to Host Conference Call and Webcast on Wednesday, November 8, 2023

LOS ANGELES, Nov. 1, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023 at 8:30 am ET (5:30 am PT) to report third quarter 2023 financial results and provide an operational update.

Conference Call Information 

Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days.

About Aadi Bioscience, Inc.

Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval and has commercialized FYARRO^® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi has also initiated PRECISION1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on the Company's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:
Marcy Graham
IR@aadibio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-third-quarter-2023-results-and-operational-update-301974366.html

SOURCE Aadi Bioscience

FAQ

When will Aadi Bioscience host the conference call and webcast?

Aadi Bioscience will host the conference call and webcast on Wednesday, November 8, 2023.

What is the purpose of the conference call and webcast?

The conference call and webcast will be held to report third quarter 2023 financial results and provide an operational update.

How can participants access the live webcast?

Participants can access the live webcast on the 'Investors & News' page of the Aadi Bioscience website at aadibio.com.

How can participants join the conference call via telephone?

Participants can register in advance at the provided link to join the conference call via telephone. A confirmation email will be sent with the dial-in number, passcode, and registrant ID.

Will there be a replay of the conference call and webcast?

Yes, a replay of the conference call and webcast will be archived on the Company's website for at least 30 days.